{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T04:57:08Z","timestamp":1764046628007},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.critrevonc.2017.06.008","type":"journal-article","created":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T04:48:20Z","timestamp":1498279700000},"page":"30-37","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Overcoming obstacles in the design of cancer anorexia\/weight loss trials"],"prefix":"10.1016","volume":"117","author":[{"given":"Jennifer G.","family":"Le-Rademacher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aminah","family":"Jatoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2017.06.008_bib0005","unstructured":"Anon, 2017. (Accessed 14 January 2017) http:\/\/www.thepharmaletter.com\/article\/enobosarm-fails-endpoints-in-ph-iii-study."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0010","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jnci\/djr556","article-title":"Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis","volume":"104","author":"Baldwin","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0015","series-title":"The Scoloderus Conspiracy","author":"Blankinship","year":"2006"},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0020","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2307\/2529880","article-title":"Optimal allocation for the comparison of proportions","volume":"38","author":"Brittain","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0025","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","article-title":"The levels of evidence and their role in evidence-based medicine","volume":"128","author":"Burns","year":"2011","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0030","unstructured":"CBRA (California Biomedical Research Association), 2017. (Accessed 14 January 2017) http:\/\/www.ca-biomed.org\/pdf\/media-kit\/fact-sheets\/CBRADrugDevelop.pdf."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0035","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1200\/JCO.2007.14.8874","article-title":"Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success","volume":"26","author":"Chan","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0040","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1001\/jama.1996.03540240035027","article-title":"Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutrition Prevention Cancer Study Group","volume":"276","author":"Clark","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0045","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1152\/japplphysiol.00045.2014","article-title":"Total body skeletal muscle mass: estimation by creatine (methyl-d3) dilution in humans","volume":"116","author":"Clark","year":"2014","journal-title":"J. Appl. Physiol. (1985)"},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0050","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11912-016-0522-0","article-title":"Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER trials)","volume":"18","author":"Crawford","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0055","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2288-13-150","article-title":"Exploratory randomized controlled trial evaluating the impact of a waiting list control design","volume":"13","author":"Cunningham","year":"2013","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0060","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2007.13.5335","article-title":"Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials","volume":"26","author":"Daugherty","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0065","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","article-title":"Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group","volume":"69","author":"Dewys","year":"1980","journal-title":"Am. J. Med."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0070","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/10543409808835243","article-title":"Power considerations when a continuous outcome variable is dichotomized","volume":"8","author":"Deyi","year":"1998","journal-title":"J. Biopharm. Stat."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0075","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/500395a","article-title":"Medical research: trial unpredictability yields predictable therapy gains","volume":"500","author":"Djulbegovic","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0080","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.2013.53.8009","article-title":"American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes","volume":"32","author":"Ellis","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0085","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jclinepi.2004.01.012","article-title":"A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale","volume":"57","author":"Eton","year":"2004","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0090","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0095","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/jcsm.12083","article-title":"Request for regulatory guidance for cancer cachexia intervention trials","volume":"6","author":"Fearon","year":"2015","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0100","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0140-6736(09)61706-2","article-title":"Biological, clinical, and ethical advances of placebo effects","volume":"375","author":"Finniss","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0105","series-title":"Fundamentals of Clinical Trials","author":"Friedman Furberg","year":"2010"},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0110","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.pain.2011.01.050","article-title":"Systematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral neuropathy \u2013magnitude and patient-related predictors","volume":"152","author":"Hauser","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0115","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0895-4356(01)00496-6","article-title":"What are the main methodological problems in the estimation of placebo effects?","volume":"55","author":"Hrobjartsson","year":"2002","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0120","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrclinonc.2015.174","article-title":"Early phase clinical trials \u2212are dose expansion cohorts needed","volume":"11","author":"Iasonos","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0125","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cct.2016.06.010","article-title":"Integrating the escalation and dose expansion studies into a unified phase 1 clinical trial","volume":"50","author":"Iasonos","year":"2016","journal-title":"Contemp. Clin. Trials"},{"issue":"August","key":"10.1016\/j.critrevonc.2017.06.008_bib0130","article-title":"Why most published research findings are false","author":"Ioannidis","year":"2005","journal-title":"PLOS"},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0135","unstructured":"Jatoi, A., Loprinzi, C., 2017. (Accessed 26 May 2017) https:\/\/www.uptodate.com\/contents\/the-role-of-parenteral-and-enteral-oral-nutritional-support-in-patients-with-cancer."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0140","unstructured":"JCO (Journal of Clinical Oncology), 2017. (Accessed 14 January 2017) http:\/\/ascopubs.org\/jco\/site\/ifc\/manuscript-guidelines.xhtml."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0145","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1200\/JCO.2013.49.2173","article-title":"Randomized, double-blind, placebo-controlled, phase 3 chemoprevention trial of selenium supplementation in patients with resected stage 1 non-small cell lung cancer: ECOG 5597","volume":"31","author":"Karp","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0150","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.2008.864","article-title":"The effect of selenium and vitamin E on risk of prostate cancer and other cancers","volume":"301","author":"Lippman","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0155","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/jnci\/82.13.1127","article-title":"Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia","volume":"82","author":"Loprinzi","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0160","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1158\/1940-6207.CAPR-10-0343","article-title":"Phase 3 trial of selenium to prevent prostate cancer in men with high-grade intraepithelial neoplasia: SWOG S9917","volume":"4","author":"Marshall","year":"2011","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0165","first-page":"233","article-title":"Parenteral nutrition in cancer patients undergoing chemotherapy: a meta-analysis","volume":"6","author":"McGeer","year":"1990","journal-title":"Nutrition"},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0170","unstructured":"NCI (National Cancer Institute), 2017a. (Accessed 14 January 2017) https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms?cdrid=45858."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0175","unstructured":"NCI (National Cancer Institute), 2017b. (Accessed 14 January 2017) https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms?cdrid=285982."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0180","first-page":"349","article-title":"Estimating the reproducibility of psychological science","volume":"28","author":"Open Science Collaboration","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0185","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S1470-2045(09)70200-1","article-title":"Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials","volume":"10","author":"Quinten","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0190","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/pds.1200","article-title":"Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics","volume":"15","author":"Schneeweiss","year":"2006","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0195","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1158\/1078-0432.CCR-15-0124","article-title":"Failures in phase 3: causes and consequences","volume":"21","author":"Seruga","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120996","article-title":"Control group design, contamination and drop out in exercise oncology trials: a systematic review","author":"Steins Bisshop","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0205","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small cell lung cancer and cachexia (ROMANA1 and ROMANA2): results from two randomized, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0210","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1471-2288-13-92","article-title":"A tutorial on sensitivity analyses in clinical trials: the what, why, when, and how","volume":"13","author":"Thabane","year":"2013","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0215","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1097\/j.pain.0000000000000333","article-title":"Increasing placebo responses over time in US clinical trials of neuropathic pain","volume":"156","author":"Tuttle","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0220","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1158\/1078-0432.CCR-13-2611","article-title":"Tumorgrafts as in vivo surrogates for women with ovarian cancer","volume":"20","author":"Weroha","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0225","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/0163278705275340","article-title":"Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience","volume":"28","author":"Yost","year":"2005","journal-title":"Eval. Health Professions"},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0230","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jclinepi.2005.07.008","article-title":"Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches","volume":"58","author":"Yost","year":"2005","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0235","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1524-4733.2005.08202.x","article-title":"Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument","volume":"8","author":"Yost","year":"2005","journal-title":"Value Health: J. Int. Soc. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.critrevonc.2017.06.008_bib0240","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1136\/ard.2008.092015","article-title":"The placebo effect and its determinants in osteoarthritis: meta-analysis of randomized controlled trials","volume":"67","author":"Zhang","year":"2008","journal-title":"Ann. Rheum. Dis."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817301506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817301506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T08:22:43Z","timestamp":1535703763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842817301506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":48,"alternative-id":["S1040842817301506"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.06.008","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming obstacles in the design of cancer anorexia\/weight loss trials","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}